

# Craig Campbell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/103793/publications.pdf>

Version: 2024-02-01

57  
papers

3,089  
citations

279798

23  
h-index

161849

54  
g-index

60  
all docs

60  
docs citations

60  
times ranked

3877  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ontario Newborn Screening for Spinal Muscular Atrophy: The First Year. Canadian Journal of Neurological Sciences, 2022, 49, 821-823.	0.5	7
2	An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries. Orphanet Journal of Rare Diseases, 2022, 17, 113.	2.7	9
3	Routine lung volume recruitment in boys with Duchenne muscular dystrophy: a randomised clinical trial. Thorax, 2022, 77, 805-811.	5.6	8
4	Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy. JAMA - Journal of the American Medical Association, 2022, 327, 1456.	7.4	43
5	Randomized phase 2 study of <scp>ACE</scp>â€œ083, a <scp>muscleâ€promoting</scp> agent, in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2022, 66, 50-62.	2.2	8
6	Newborn Screening for Spinal Muscular Atrophy: Ontario Testing and Follow-up Recommendations. Canadian Journal of Neurological Sciences, 2021, 48, 504-511.	0.5	18
7	<scp>12â€Month</scp> progression of motor and functional outcomes in congenital myotonic dystrophy. Muscle and Nerve, 2021, 63, 384-391.	2.2	5
8	Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study. Neurotherapeutics, 2021, 18, 1127-1136.	4.4	28
9	Î±â€tropomyosin gene (TPM3) mutation in an infant with nemaline myopathy. Clinical Case Reports (discontinued), 2021, 9, 1672-1676.	0.5	3
10	Health related quality of life in young, steroid-naïve boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2021, 31, 1161-1168.	0.6	4
11	Magnetic Resonance Imaging Findings Are Associated with Long-Term Global Neurological Function or Death after Traumatic Brain Injury in Critically Ill Children. Journal of Neurotrauma, 2021, 38, 2407-2418.	3.4	1
12	Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research, 2021, 10, 1337-1347.	1.4	6
13	Fatigue in young people with Duchenne muscular dystrophy. Developmental Medicine and Child Neurology, 2020, 62, 245-251.	2.1	19
14	Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research, 2020, 9, 973-984.	1.4	41
15	Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscular Disorders, 2020, 30, 492-502.	0.6	40
16	A National Spinal Muscular Atrophy Registry for Real-World Evidence. Canadian Journal of Neurological Sciences, 2020, 47, 810-815.	0.5	6
17	Drisapersen associated with elevated serum factor VIII levels in Duchenne muscular dystrophy. Neurology, 2020, 94, 538-540.	1.1	2
18	Further delineation of TBCK - Infantile hypotonia with psychomotor retardation and characteristic facies type 3. European Journal of Medical Genetics, 2019, 62, 273-277.	1.3	11

#	ARTICLE	IF	CITATIONS
19	Patient-reported study of the impact of pediatric-onset myotonic dystrophy. <i>Muscle and Nerve</i> , 2019, 60, 392-399.	2.2	8
20	Agitated behavior scale in pediatric traumatic brain injury. <i>Brain Injury</i> , 2019, 33, 916-921.	1.2	3
21	A Phenotypic Description of Congenital Myotonic Dystrophy using PhenoStacks. <i>Journal of Neuromuscular Diseases</i> , 2019, 6, 341-347.	2.6	2
22	Body composition in patients with congenital myotonic dystrophy. <i>Muscle and Nerve</i> , 2019, 60, 176-179.	2.2	2
23	Distal arthrogyriposis type 5 and <i>PIEZO2</i> novel variant in a Canadian family. <i>American Journal of Medical Genetics, Part A</i> , 2019, 179, 1034-1041.	1.2	6
24	Consensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1. <i>Neurology: Clinical Practice</i> , 2019, 9, 443-454.	1.6	32
25	Twinkle-Associated Mitochondrial DNA Depletion. <i>Pediatric Neurology</i> , 2019, 90, 61-65.	2.1	11
26	The Canadian Neuromuscular Disease Registry: Connecting patients to national and international research opportunities. <i>Paediatrics and Child Health</i> , 2018, 23, 20-26.	0.6	11
27	Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. <i>New England Journal of Medicine</i> , 2018, 378, 625-635.	27.0	977
28	Treating pediatric neuromuscular disorders: The future is now. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 804-841.	1.2	93
29	Prenatal, Neonatal, and Early Childhood Features in Congenital Myotonic Dystrophy. <i>Journal of Neuromuscular Diseases</i> , 2018, 5, 331-340.	2.6	13
30	Orofacial strength, dysarthria, and dysphagia in congenital myotonic dystrophy. <i>Muscle and Nerve</i> , 2018, 58, 413-417.	2.2	20
31	Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. <i>Contemporary Clinical Trials</i> , 2017, 58, 34-39.	1.8	56
32	Physical function and mobility in children with congenital myotonic dystrophy. <i>Muscle and Nerve</i> , 2017, 56, 224-229.	2.2	14
33	The Effect of Noninvasive Positive Pressure Ventilation on Pneumonia Hospitalizations in Children With Neurological Disease. <i>Child Neurology Open</i> , 2017, 4, 2329048X1668902.	1.1	2
34	The relationship between quality of life and health-related quality of life in young males with Duchenne muscular dystrophy. <i>Developmental Medicine and Child Neurology</i> , 2017, 59, 1152-1157.	2.1	13
35	We need a "made in Canada" orphan drug framework. <i>Cmaj</i> , 2017, 189, E1274-E1275.	2.0	7
36	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 1489-1498.	13.7	365

#	ARTICLE	IF	CITATIONS
37	Myostatin inhibitor ACE031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. <i>Muscle and Nerve</i> , 2017, 55, 458-464.	2.2	176
38	Pharmacological therapy for the prevention and management of cardiomyopathy in Duchenne muscular dystrophy: A systematic review. <i>Neuromuscular Disorders</i> , 2017, 27, 4-14.	0.6	23
39	Seizures Related to Hypomagnesemia. <i>Child Neurology Open</i> , 2016, 3, 2329048X1667483.	1.1	29
40	Developmental Milestones and Quality of Life Assessment in a Congenital Myotonic Dystrophy Cohort. <i>Journal of Neuromuscular Diseases</i> , 2016, 3, 405-412.	2.6	7
41	Disease burden and functional outcomes in congenital myotonic dystrophy. <i>Neurology</i> , 2016, 87, 160-167.	1.1	33
42	Myotonic dystrophy type 1. <i>Cmaj</i> , 2016, 188, 1033-1033.	2.0	10
43	Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy. <i>Developmental Medicine and Child Neurology</i> , 2016, 58, 698-705.	2.1	41
44	Factors Associated With Health-Related Quality of Life in Children With Duchenne Muscular Dystrophy. <i>Journal of Child Neurology</i> , 2016, 31, 879-886.	1.4	28
45	Health-Related Quality of Life in Children with Duchenne Muscular Dystrophy: A Review. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, 313-324.	2.6	13
46	Ataluren treatment of patients with nonsense mutation dystrophinopathy. <i>Muscle and Nerve</i> , 2014, 50, 477-487.	2.2	357
47	Congenital Myotonic Dystrophy: Canadian Population-Based Surveillance Study. <i>Journal of Pediatrics</i> , 2013, 163, 120-125.e3.	1.8	57
48	The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia. <i>Human Mutation</i> , 2013, 34, 1449-1457.	2.5	94
49	The CNDR: Collaborating to Translate New Therapies for Canadians. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 698-704.	0.5	16
50	Symptomatic dystrophinopathies in female children. <i>Neuromuscular Disorders</i> , 2011, 21, 172-177.	0.6	27
51	Infantile muscular dystrophy in Canadian aboriginals is an $\alpha$ -crystallinopathy. <i>Annals of Neurology</i> , 2011, 69, 866-871.	5.3	62
52	Case 2: Chronic daily headache in a teenager. <i>Paediatrics and Child Health</i> , 2010, 15, 263-266.	0.6	1
53	Congenital myotonic dystrophy in a national registry. <i>Paediatrics and Child Health</i> , 2010, 15, 514-518.	0.6	15
54	Duchenne Muscular Dystrophy: Canadian Paediatric Neuromuscular Physicians Survey. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 195-205.	0.5	27

#	ARTICLE	IF	CITATIONS
55	Subacute Sclerosing Panencephalitis: Results of the Canadian Paediatric Surveillance Program and review of the literature. BMC Pediatrics, 2005, 5, 47.	1.7	41
56	Congenital Myotonic Dystrophy: Assisted Ventilation Duration and Outcome. Pediatrics, 2004, 113, 811-816.	2.1	76
57	Deflazacort for the treatment of Duchenne Dystrophy: A systematic review. BMC Neurology, 2003, 3, 7.	1.8	50